Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 921-929

  Hocker B ^a   Zencke, S ^a   Pape, L ^b   Krupka, K ^a   Koster L ^a   Fichtner, A ^a   Dello Strologo, L ^d   Guzzo, I ^d   Topaloglu, R ^e   Kranz, B ^f   Konig J ^f   Bald, M ^g   Webb, N J A ^h   Noyan, A ⁱ   Dursun, H ⁱ   Marks, S ^j   Ozcakar, Z B ^k   Thiel, F ^l   Billing, H ^m   Pohl, M ⁿ   Fehrenbach, H ^o   Schnitzler, P ^a   Bruckner, T ^c   Ahlenstiel Grunow, T ^b   Tonshoff B ^a   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e HACETTEPE UNIVERSITY   (Turkey)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g Department of Pediatric Hematology and Oncology   (Germany)

^h ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

ⁱ BASKENT UNIVERSITY   (Turkey)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k ANKARA UNIVERSITY   (Turkey)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o Children's Hospital   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; EVEROLIMUS; GANCICLOVIR; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; TREATMENT DURATION; VIRUS REPLICATION; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY; VIROLOGY;

CHILD; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VIRUS REPLICATION;

EID: 84959542547     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13649     Document Type: Article

References (40)

1. Opelz G, Dohler B,. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation 2015; 99: 1197-1202.
2. Smith JM, Corey L, Bittner R, et al., Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586.
3. Smith JM, Dharnidharka VR,. Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol 2014; 30: 741-748.
4. Dzabic M, Rahbar A, Yaiw KC, et al., Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011; 53: 969-976.
5. Li L, Chaudhuri A, Weintraub LA, et al., Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11: 187-195.
6. Sagedal S, Hartmann A, Nordal KP, et al., Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
7. Sagedal S, Nordal KP, Hartmann A, et al., A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
8. Sagedal S, Nordal KP, Hartmann A, et al., The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
9. Smedbraten YV, Sagedal S, Leivestad T, et al., The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant 2014; 28: 120-126.
10. Moorman NJ, Shenk T,. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260-5269.
11. Araki K, Turner AP, Shaffer VO, et al., mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
12. Ferrer IR, Araki K, Ford ML,. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011; 11: 654-659.
13. Ferrer IR, Wagener ME, Robertson JM, et al., Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8 + T cell responses. J Immunol 2010; 185: 2004-2008.
14. Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T,. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009; 9: 2655-2661.
15. Katholnig K, Linke M, Pham H, Hengstschlager M, Weichhart T,. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem Soc Trans 2013; 41: 927-933.
16. Matas AJ, Smith JM, Skeans MA, et al., OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 2014; 14 (Suppl 1): 11-44.
17. Plotnicki L, Kohl CD, Hocker B, et al., The CERTAIN Registry: A novel, web-based registry and research platform for pediatric renal transplantation in Europe. Transpl Proc 2013; 45: 1414-1417.
18. Kotton CN, Kumar D, Caliendo AM, et al., Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360.
19. Humar A, Michaels M,. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
20. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
21. Jassal SV, Roscoe JM, Zaltzman JS, et al., Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9: 1697-1708.
22. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.11 Paediatrics (specific problems). Nephrol Dial Transplant: 2002; 17 (Suppl 4): 55-58.
23. European Expert Group on Renal Transplantation (EBPG), European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant: 2000; 15 (Suppl 7): 1-85.
24. Kotton CN, Kumar D, Caliendo AM, et al., International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
25. Vaudry W, Ettenger R, Jara P, et al., Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009; 9: 636-643.
26. Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
27. Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
28. Schwartz GJ, Work DF,. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4: 1832-1843.
29. Harrell FE,. Multivariable Modeling Strategies. In:, Harrell FE, editor. Regression modeling strategies-with applications to linear models, logistic regression, and survival analysis. New York, Berlin, Heidelberg: Springer, 2001; II: p. 63-66.
30. Clayton D, Hills M,. Choice and interpretation of models. In:, Clayton D, Hills M, editors. Statistical models in epidemiology. Oxford: University Press, 1993; p. 271-273.
31. Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al., Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003; 75: 1538-1543.
32. Höcker B, Zencke S, Krupka K, et al., Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir. Transplantation. In press 2015. doi: 10.1097/TP.0000000000000888
33. Andrassy J, Hoffmann VS, Rentsch M, et al., Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis. Transplantation 2012; 94: 1208-1217.
34. Tedesco-Silva H, Felipe C, Ferreira A, et al., Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant: 2015; 15: 2655-2664. doi: 10.1111/ajt.13327
35. Nashan B, Gaston R, Emery V, et al., Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085.
36. Brennan DC, Aguado JM, Potena L, et al., Effect of maintenance immunosuppressive drugs on virus pathobiology: Evidence and potential mechanisms. Rev Med Virol 2013; 23: 97-125.
37. Clippinger AJ, Maguire TG, Alwine JC,. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85: 3930-3939.
38. Weichhart T, Costantino G, Poglitsch M, et al., The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
39. Vitko S, Margreiter R, Weimar W, et al., Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-1540.
40. Ekberg H, Bernasconi C, Noldeke J, et al., Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004-2010.